Effect of age, weight, and CYP2C19 genotype on escitalopram exposure

Journal of Clinical Pharmacology

Volumn 50, Issue 1, 2010, Pages 62-72

  Jin, Yuyan ^a   Pollock, Bruce G ^b,c   Frank, Ellen ^b   Cassano, Giovanni B ^c,d   Rucci, Paola ^b   Müller, Daniel J ^c   Kennedy, James L ^c   Forgione, Rocco Nicola ^d   Kirshner, Margaret ^b   Kepple, Gail ^b   Fagiolini, Andrea ^e   Kupfer, David J ^c   Bies, Robert R ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

CYP2C19 gene; Escitalopram; NONMEM; Pharmacogenetics; Pharmacokinetics; SPECTRUM study

Indexed keywords

CYTOCHROME P450 2C19; ESCITALOPRAM;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; ASIAN; BODY MASS; BODY WEIGHT; CASE REPORT; CAUCASIAN; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; ERROR; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; POPULATION RESEARCH; PSYCHOTHERAPY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT DURATION; UNITED STATES;

ADULT; AGE FACTORS; AGED; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; BODY MASS INDEX; BODY WEIGHT; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; ITALY; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; UNITED STATES;

EID: 72749114323     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337946     Document Type: Article

References (35)

1. Thase ME Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother. 2006 ; 7: 429-440.
2. Demyttenaere K., Bruffaerts R., Posada-Villa J., et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004 ; 291: 2581-2590.
3. Burke WJ, Gergel I., Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002 ; 63: 331-336.
4. Rapaport MH, Bose A., Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry. 2004 ; 65: 44-49.
5. Wade A., Michael Lemming O., Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2002 ; 17: 95-102.
6. Davidson JR, Bose A., Korotzer A., Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004 ; 19: 234-240.
7. Stahl SM, Gergel I., Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003 ; 64: 1322-1327.
8. Owens MJ, Knight DL, Nemeroff CB Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001 ; 50: 345-350.
9. Gorman JM, Korotzer A., Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr. 2002 ; 7: 40-44.
10. Lepola U., Wade A., Andersen HF Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol. 2004 ; 19: 149-155.
11. Crone CC, Gabriel GM Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004 ; 43: 361-394.
12. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004 ; 50: 57-64.
13. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007 ; 46: 281-290.
14. Sogaard B., Mengel H., Rao N., Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005 ; 45: 1400-1406.
15. Frank E., Cassano GB, Rucci P., et al. Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. Clin Trials. 2008 ; 5: 253-261.
16. Sheiner LB, Rosenberg B., Marathe VV Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977 ; 5: 445-479.
17. Williams PJ, Ette EI The role of population pharmacokinetics in drug development in light of the Food and Drug Administration?s ĝ€? Guidance for Industry: population pharmacokinetics. ? Clin Pharmacokinet. 2000 ; 39: 385-395.
18. Kennedy J., Tuleu I., Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008 ; 14: 553-560.
19. Bies RR, Feng Y., Lotrich FE, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 2004 ; 44: 1352-1359.
20. Jin Y., Pollock BG, Kirshner M., et al. Effect of different dosing report methods on estimation of pharmacokinetic parameters for escitalopram. J Clin Pharmacol. 2007 ; 47: 1205.
21. Dhillon S., Scott LJ, Plosker GL Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs. 2006 ; 20: 763-790.
22. Areberg J., Christophersen JS, Poulsen MN, et al. The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J. 2006 ; 8: E14 - E19.
23. Rosenborg S., Mwinyi J., Andersson M., et al. Kinetics of omeprazole and escitalopram in relation to the CYP 2C19*17 allele in healthy subjects. Eur J Clin Pharmacol. 2008 ; 64: 1175-1179.
24. Rudberg I., Mohebi B., Hermann M., et al. Impact of the ultra-rapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008 ; 83: 322-327.
25. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008 ; 48: 157-165.
26. Feng Y., Pollock BG, Ferrell RE, et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol. 2006 ; 61: 558-569.
27. Booth BP, Gobburu JV Considerations in analyzing single-trough concentrations using mixed-effects modeling. J Clin Pharmacol. 2003 ; 43: 1307-1315.
28. Pollock BG, Perel JM, Kirshner M., et al. S-mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol. 1991 ; 40: 609-611.
29. Bigos KL, Pollock BG, Aizenstein HJ, et al. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology. 2008 ; 33: 3221-3225.
30. Juurlink DN, Mamdani MM, Kopp A., Redelmeier DA The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry. 2006 ; 163: 813-821.
31. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004 ; 164: 327-332.
32. Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing ? CNS Drugs. 2006 ; 20: 143-151.
33. Pollock BG, Laghrissi-Thode F., Wagner WR Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000 ; 20: 137-140.
34. Richards JB, Papaioannou A., Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007 ; 167: 188-194.
35. Barak Y., Swartz M., Levy D., Weizman R. Age-related differences in the side effect profile of citalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2003 ; 27: 545-548.